The Mikaela Naylon Give Kids a Chance Act amends the Federal Food, Drug, and Cosmetic Act to create specific requirements for "molecularly targeted pediatric cancer investigations," adjusts how pediatric study obligations apply to single‑ingredient and combination cancer drugs, and clarifies FDA authority and timelines for implementing those requirements. The bill also tightens enforcement procedures for pediatric study requirements, narrows the scope of orphan‑drug exclusivity to particular approved uses or indications, extends the rare pediatric disease priority review voucher (PRV) program, and funds other programs affecting pediatric drug development and transplantation infrastructure.
This is consequential for sponsors and regulators: it prescribes study design expectations, creates procedural guardrails (advance determinations of applicability and required submissions), and raises reporting and transparency demands (GAO and FDA reports, generic formulation disclosures). The package mixes incentives (extended PRVs, program funding) with new obligations and enforcement mechanics that could materially change development programs for pediatric oncology and rare disease products.
At a Glance
What It Does
The bill amends section 505B to require molecularly targeted pediatric cancer investigations in specified circumstances, allows limited combination‑drug pediatric investigations, and mandates FDA guidance and timing for implementation. It adds procedural protections before enforcement of pediatric study obligations, extends authority to issue rare pediatric disease priority review vouchers to September 30, 2029, and redefines orphan exclusivity to apply to the same approved use or indication rather than a broader disease category.
Who It Affects
Pharmaceutical sponsors of oncology drugs (including those seeking pediatric or adult cancer approvals), FDA reviewers and compliance staff, pediatric oncology investigators, organ procurement organizations and transplant centers (through OPTN modernization and fee authority), generic applicants seeking to match inactive ingredients, and entities engaged in international regulatory cooperation with FDA.
Why It Matters
The law aims to accelerate and standardize pediatric oncology data while closing perceived regulatory loopholes that let sponsors claim broad exclusivity. It couples incentives (PRVs, program funding) with procedural and enforcement changes that increase FDA oversight and transparency — altering development timelines, compliance risk, and commercial exclusivity calculations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act rewrites the mechanics of how the FDA requires pediatric studies for molecularly targeted cancer drugs. It expands section 505B to define when a molecularly targeted pediatric cancer investigation is required — covering the applicant’s drug alone and, in narrowly drawn circumstances, that drug in combination with other active ingredients already approved for adults or parts of standard pediatric care.
The statute requires those pediatric investigations to be designed to produce clinically meaningful pediatric dosing, safety, and preliminary efficacy data using age‑appropriate formulations.
The bill builds in process controls for sponsors and the agency. FDA must determine before an applicant’s initial pediatric study plan is due whether the application falls under the new combination or single‑agent rules, and the agency may ask for completed preclinical study results at the time the initial plan is submitted.
The Act sets specific guidance deadlines (draft guidance within 12 months; final guidance within 12 months after closing comments) and delays applicability of the new 505B rules to applications submitted until three years after enactment.On enforcement, the Act tightens the path the FDA must follow before pursuing statutory remedies for missed pediatric obligations: the agency must issue a noncompliance letter, give the sponsor 45 days to respond, and make a reasoned due‑diligence determination before treating the failure as actionable. The bill also establishes a limited transition period — FDA may only take section 303 enforcement for failures that occur 180 days after enactment.Outside pediatric oncology, the Act extends the rare pediatric disease PRV program through September 30, 2029, requires the PRV user fee to be paid at application submission, and directs a GAO study on PRV effectiveness.
It narrows orphan‑drug exclusivity so the seven‑year period protects the same approved use or indication rather than a broad disease label, and makes that definition apply regardless of when designation or approval occurred. Additional provisions fund a pediatric‑studies program ($25 million per fiscal year 2026–2028), modernize the Organ Procurement and Transplantation Network (encouraging EHR/APIs and authorizing temporary registration fees), create an FDA Abraham Accords Office abroad to provide regulatory technical assistance, demand more transparency on inactive ingredients for generic applications, and increase the Medicare Improvement Fund allocation.
The Five Things You Need to Know
The bill adds a new path for pediatric combination‑drug investigations: an applicant’s drug may trigger a pediatric study requirement when combined with an active ingredient already approved under 505(j) or 351(k) if that ingredient is part of the standard of care for pediatric cancer.
FDA must issue draft guidance on implementing the 505B changes within 12 months of enactment and finalize guidance within 12 months after the comment period closes.
The new 505B obligations apply only to applications submitted on or after the date three years after enactment; FDA may require preclinical study results be submitted with the initial pediatric study plan.
Before invoking statutory enforcement under section 303 for missed pediatric study duties, FDA must send a noncompliance letter, allow a 45‑day written response, and determine whether the sponsor lacked due diligence; section 303 enforcement is limited to failures occurring 180 days or more after enactment.
Orphan‑drug exclusivity is redefined to protect the same approved use or indication (not an entire disease category), and that narrower meaning applies retroactively to previously designated or approved drugs.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
New rules for molecularly targeted pediatric cancer investigations
This provision rewrites 505B(a)(3) to define a 'molecularly targeted pediatric cancer investigation' and to permit narrow combination investigations. It distinguishes two tracks: (A) investigations for the application drug alone, and (B) limited investigations when the applicant’s adult‑cancer product is used with another active ingredient that is either an established pediatric standard of care or an adult cancer product held by the same sponsor and directed at a target relevant to pediatric disease. Practically, sponsors must plan studies that produce age‑appropriate dosing, safety, and preliminary efficacy data; FDA may require submission of completed preclinical results with the initial pediatric study plan.
Advance determinations and guidance timetables
The Act requires FDA to determine whether the single‑agent or combination pathway applies before the initial pediatric study plan deadline. It imposes a clear timetable for agency guidance — draft in 12 months, final within 12 months after comments — and delays the effective date of these requirements for three years to let sponsors and regulators prepare. That combination of advance determinations and delayed applicability intends to reduce surprise compliance obligations at the time of application.
Due‑diligence protections before enforcement
This section modifies 505B(d) to require a formal noncompliance letter, a 45‑day written response window, and an explicit agency finding that the sponsor lacked 'due diligence' before resorting to section 303 enforcement. It also clarifies that FDA cannot enforce retroactively against products no longer marketed, and institutes a 180‑day transition rule limiting immediate enforcement.
Expanded PREA enforcement reporting
The bill augments FDA's PREA reporting duties to Congress, requiring evaluation of compliance with deferral deadlines and an explicit listing of penalties, settlements, or payments under section 303 tied to 505B violations — including drug name, sponsor, and penalty amount. That increases transparency about enforcement outcomes and provides congressional oversight data.
PRV extension and GAO effectiveness study
The statute extends the rare pediatric disease priority review voucher authority through September 30, 2029, and changes the PRV user fee to be due at application submission. It also mandates a GAO study examining whether PRVs stimulated development, who received vouchers (company size and transfers), voucher values, time to use, and impacts on FDA workload and prioritization.
Narrowing orphan‑drug exclusivity to approved use or indication
This change tightens section 527 so the seven‑year exclusivity protects the 'same approved use or indication' rather than a broad disease label. The amendment applies regardless of when designation or approval occurred, limiting the ability of later entrants to be blocked based on a sponsor’s approval for a different indication within the same disease.
Dedicated funding for pediatric studies program
The bill appropriates $25 million per year for fiscal years 2026–2028 to the existing program for pediatric drug studies under the Public Health Service Act, creating a short multi‑year funding stream aimed at supporting study infrastructure or grants tied to pediatric drug testing.
OPTN modernization and temporary registration fees
Amendments encourage OPTN integration with hospital EHRs via APIs, permit remote electronic access for organ procurement organizations (with HIPAA compliance), and direct creation of a more frequent transplant dashboard. For operations, the bill authorizes collecting registration fees from members placing candidates on the match list to support OPTN operations, requires public posting of amounts and uses, mandates a GAO review in two years, and sunsets fee authority after three years.
International office, generics transparency, and Medicare fund increase
The Act creates an FDA Abraham Accords Office to be established in an Abraham Accords country within two years to provide technical assistance and facilitate regulatory interactions; requires a report to Congress after three years. It adds a disclosure pathway for abbreviated new drug applicants to ask FDA whether inactive ingredients are qualitatively and quantitatively the same as the listed drug, with procedures limiting rescission of that determination and statutory protections for trade secrets. Finally, it raises the Medicare Improvement Fund allocation in statute from approximately $1.403B to $2.622B.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Children with cancer and their families — the Act pushes sponsors and FDA toward generating pediatric‑specific dosing, safety, and preliminary efficacy data and narrows ways sponsors can use broad exclusivity to delay pediatric access.
- Academic and clinical pediatric oncology researchers — clearer expectations for study design, a funded pediatric studies program, and required pediatric data submissions should create more standardized trial opportunities and data flow.
- Smaller companies targeting rare pediatric diseases — extension of the rare‑pediatric PRV program and a GAO study aimed at assessing PRV impact may preserve an important commercial incentive for investment in pediatric indications.
- Transplant candidates and policy analysts — OPTN modernization (EHR/APIs, remote access) and more frequent data dashboards aim to improve organ matching transparency and tracking of wasted organs.
- Regulators in Abraham Accords countries and multinational manufacturers — the Abraham Accords Office promises targeted FDA technical assistance and a conduit for regulatory convergence, reducing friction on cross‑border manufacturing oversight.
Who Bears the Cost
- Pharmaceutical sponsors (especially oncology developers) — new pediatric study expectations, earlier preclinical data submissions, and narrower orphan exclusivity increase development costs, planning complexity, and potential reduction in exclusivity value.
- Small sponsors reliant on exclusivity strategies — redefining orphan exclusivity to specific indications can reduce the protective scope they previously relied on to block competitors.
- FDA — implementation requires issuing guidance, making advance applicability determinations, handling more procedural due‑diligence reviews, standing up or coordinating with the Abraham Accords Office, and expanded reporting to Congress, all of which demand staff time and resources.
- Organ Procurement and Transplantation Network members and hospitals — encouraged EHR integrations and providing remote access will require IT investments and process changes; some OPTN members will pay registration fees for candidate listings during the temporary fee window.
- Manufacturers of listed drugs — the new transparency pathway for inactive ingredients could trigger additional information requests and adjudication processes, and, while trade secret protections remain, it increases administrative interaction with FDA.
Key Issues
The Core Tension
The central dilemma is accelerating robust pediatric cancer data and closing exclusivity loopholes versus imposing new, potentially costly regulatory obligations that could deter development or shift investment away from smaller sponsors; the Act attempts to pair incentives with requirements, but that mix inevitably forces tradeoffs between speed, certainty, and the economic calculus of rare‑disease drug development.
The Act juggles incentives and obligations in ways that will matter in practice. Requiring molecularly targeted pediatric investigations and tighter study design standards is intended to produce usable pediatric labeling data, but the combination‑drug carve outs are narrowly drawn and hinge on FDA judgments (e.g., whether an active ingredient is part of pediatric standard of care or whether a target is "substantially relevant" to pediatric cancer).
Those determinations can be litigated territory or sources of delay if FDA and sponsors disagree. The three‑year delay for applicability softens immediate disruption but also means older approvals remain governed by prior rules, producing a two‑tier regulatory environment for several years.
Implementation risks are practical and procedural. The due‑diligence procedural guardrails (noncompliance letter + 45‑day response) protect sponsors but create additional adjudicatory steps that will consume FDA review capacity.
The requirement that FDA list penalties or settlements for 505B noncompliance increases transparency but may deter settlements or change negotiation dynamics. OPTN fee authority is temporary and earmarked to operations, but shifting costs to network members and hospitals could raise access or equity issues depending on how fees are structured and distributed.
Finally, the generics disclosure regime balances applicant clarity against proprietary risk; statutory language protects trade secrets but creates new avenues for revealing formulation differences that originators will watch closely.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.